{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255167","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.935495+00:00","generated_at":"2026-05-30T02:27:46.308040+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23","bullets":["GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.","Adjusted gross margin 50.7%; adjusted operating margin 14.9% vs 3.7%.","Full-year 2024 revenue guidance narrowed to $630-$639M (midpoint unchanged).","CDMO revenue and orders each grew ~20% YoY; new modalities record quarterly revenue.","Announced definitive agreement to acquire chromatography firm Tantti Laboratory Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255167","json":"https://secwatch.observer/filing/0001193125-24-255167.json","markdown":"https://secwatch.observer/filing/0001193125-24-255167.md","text":"https://secwatch.observer/filing/0001193125-24-255167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/0001193125-24-255167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312524255167/d811195d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:27:46.308040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}